29 research outputs found

    Maintenance of glial progenitor-like phenotype, but enhanced CD133 expression in high-grade gliomas.

    No full text
    <p>In addition to multiple glial progenitor cell markers, a high proportion of glioma cells co-expressing CD133 was detected in most of the high-grade glioma specimens. Dot-plot profiles of glial progenitor cell surface markers and CD133 expression on high-grade glioma cells from representative patients (#14 (A) and #22 (B)) are shown. Freshly isolated glioma cells were simultaneously stained with the indicated antibodies. The hematopoietic cells were distinguished with anti-CD45 staining. The numbers in each quadrate represent the percentages of the cells stained positively or negatively by the respective antibodies.</p

    Low-grade glioma cells concurrently express multiple cell surface markers characteristic of adult human glial progenitors.

    No full text
    <p>Dot-plot profiles of glial progenitor cell surface markers and CD133 expression on low-grade glioma cells from two representative patients (#1 (A) and #4 (B)) are shown. Freshly isolated glioma cells were simultaneously stained with the indicated antibodies. The hematopoietic cells were distinguished with anti-CD45 staining. The numbers in each quadrate represent the percentages of the cells stained positively or negatively by the respective antibodies.</p

    Karyotype analysis of short-term cultured glioma cells

    No full text
    <p>Freshly isolated glioma cells were cultured and analyzed for karyotype between passage 3 to 4. The number in brackets represents the number of the indicated karyotype.</p

    Differential expression of PDGFRA in glioma subtypes and its association with patient survival time.

    No full text
    <p>In both GSE16011 (<b>A, B</b>) and Rembrandt (<b>C, D</b>) data sets, PDGFRA expression (Mean ± 2 SEM, SEM: standard error of the mean) was highly variable among the samples of each morphological subtype (<b>A</b> and <b>C.</b> NT: non-tumor; AII, astrocytoma grade II; AIII: astrocytoma grade III; GBM, glioblastoma; OD: oligodendroglioma; OA: oligoastrocytoma). Low-grade gliomas showed significantly higher levels of PDGFRA expression compared to high-grade gliomas (<b>B</b> and <b>D</b>). Kaplan-Meier plots showed that in both GSE16011 (<b>E</b>) and Rembrandt (<b>F</b>) data sets, the survival of patients with the upper 25% PDGFRA expression (PDGFRA-high) in glioma samples irrespective of their morphological diagnosis was significantly longer compared with those glioma patients with PDGFRA expression at the lowest 25% (PDGFRA-low) and the intermediate 50% (log-rank test).</p

    Co-expression of neuronal and glial markers in high-grade glioma cells

    No full text
    <p>The GFAP and NSE staining was performed in the fixed glioma specimens from the same surgical procedures as those used for generating viable cells. The staining was semi-quantitatively evaluated. +++: markedly positive staining; ++: moderately positive staining; +: low positive; −: no positive staining in the tumor.</p

    Expression of neural stem cell and glial progenitor surface markers in low- and high-grade glioma specimens analyzed.

    No full text
    <p>Freshly prepared or thawed glioma cells were first incubated with non-specific mouse IgG1 mAb, cells were subsequently incubated with APC conjugated anti-CD45 mAb in combination with FITC conjugated anti-CD44, or anti-CD24 mAbs or PE conjugated anti-PDGFRα, anti-EGFR, anti-CD133 mAbs. For A2B5 and O4 staining, cells were incubated with unconjugated A2B5 or O4 mAb respectively and subsequently stained with PE conjugated rat anti-mouse IgM. Cells negatively stained with 7-AAD were analyzed for cell surface marker expression. Data shown are the percentages of CD45 negative cells positively stained for indicated cell surface markers.</p>*<p>: secondary GBM. UD: undetectable; ND: not done. PNET: primitive neuroectodermal tumor.</p

    Vessel or glioma origin of CD133 expressing cells.

    No full text
    <p>In contrast to high-grade glioma specimens, CD133 expressing cells detected in low-grade glioma specimens are predominantly derived from blood vessel endothelial cells. Dot-plot profiles of CD133 expression versus CD45 and/or CD31 expression of cells from glioma specimens of indicated patients are shown. The numbers in each quadrate represent the percentages of the cells stained positively or negatively by the respective antibodies.</p

    Enriched FGF2 expression in low-grade gliomas.

    No full text
    <p>The relative expression levels of FGF2 (Mean ± 2SEM) were analyzed in the GSE16011 (<b>A</b> and <b>B</b>) and the Rembrandt (<b>C</b> and <b>D</b>) data sets according to the morphological diagnosis of gliomas (<b>A</b> and <b>C</b>). Low-grade gliomas showed significantly higher levels of FGF2 expression compared to high-grade gliomas (<b>B</b> and <b>D</b>, <i>t</i> test).</p

    FGF2-dependent maintenance of PDGFRA expression.

    No full text
    <p><b>A</b>) Percentages of PDGFRA-positive cells in the indicated glioma cell lines (L1–L9) following a culture for 7 to 10 days with (+) or without (−) FGF2 support. <b>B</b>) Maintenance of PDGFRA expression in glioma cells (L1 and L2) cultured with the support of FGF2 alone for 7 days. In contrast to PDGFRA, the expression of CD44 was not affected by FGF2. <b>C</b>) RT-PCR detection of PDGFRA expression in the parallel cultures as in <b>B</b>).</p
    corecore